The National Institutes of Health (NIH) is funding a clinical trial testing a new therapy for dengue.
The trial will expose participants “to a weakened strain of dengue virus that causes a mild form of the disease” and then they will be given “an investigational therapeutic at various doses to assess its safety and ability to lessen symptoms,” according to an NIH release.
The medication being tried is called AV-1, “an investigational human monoclonal antibody therapeutic developed by AbViro (Bethesda, Maryland), to mitigate clinical symptoms when administered before and after dengue virus infection.” A previous trial determined the safety of AV-1. The new study plans to test the treatment’s efficacy. 84 adults will be participating.
